Skip to main
OTLK
OTLK logo

OTLK Stock Forecast & Price Target

OTLK Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Outlook Therapeutics Inc. recently received marketing authorization for ONS-5010, a significant milestone marking its entry into the European Union and UK markets for treating wet age-related macular degeneration, which enhances its revenue potential. Although general and administrative expenses rose by 106.2% year-over-year to $11.9 million, this increase is indicative of the company's commitment to scaling operations and advancing its clinical pipeline, reflected in the substantial 113.3% surge in research and development expenses to $9.7 million. Positive results from the NORSE EIGHT trial, demonstrating noninferiority to a competitor product, alongside strategic collaborations aimed at supporting commercial launches, position Outlook Therapeutics favorably for future growth in the ophthalmic market.

Bears say

In the first quarter of 2024, Outlook Therapeutics reported a significant loss per share of $0.78, coupled with a widening operating loss to $21.6 million, which exceeded prior estimates and reflects deteriorating financial health. The results from the NORSE EIGHT clinical study were disappointing, as the company failed to meet critical non-inferiority endpoints, raising concerns about the viability of its lead product, ONS-5010. Additionally, potential regulatory hurdles could impede the commercialization process, and there are risks of shareholder dilution if the company necessitates equity financing to navigate its financial challenges.

OTLK has been analyzed by 10 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Outlook Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Outlook Therapeutics Inc (OTLK) Forecast

Analysts have given OTLK a Buy based on their latest research and market trends.

According to 10 analysts, OTLK has a Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.26, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.26, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Outlook Therapeutics Inc (OTLK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.